ABO Blood Group Type Association With COVID-19 Severity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

599 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-10

Study Completion Date

2023-05-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to different pathogens, such as hepatitis B virus, MERS-COV, SARS-COV, norovirus, and malaria, to name a few. As such, the association of ABO blood groups and COVID-19 infection and disease severity has come into question.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection

NCT00688389

Dengue Fever

UNKNOWN

Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year

NCT04910971

COVID-19 Vaccine Corona Virus Infection Vaccine Adverse Reaction +3 more

UNKNOWN

Notification of Donors With Positive Microbiology Markers

NCT01050881

Human Immunodeficiency Virus Hepatitis B Hepatitis C +2 more

COMPLETED

Risk Factors and Characteristics of COVID 19 Infection in Patients With Haematological Diseases

NCT04930731

Covid19

UNKNOWN

Using Mixed-methods Approach to Explore the Long-term Effects of COVID-19

NCT05303103

Covid19

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to different pathogens, such as hepatitis B virus, MERS-COV, SARS-COV, norovirus, and malaria, to name a few. As such, the association of ABO blood groups and COVID-19 infection and disease severity has come into question.

Early reports have indicated a significant relationship of ABO blood group types to the risk of infection with SARS-CoV-2. Specifically, the first systematic review and meta-analysis by Wu et al. in October 2020 cited that blood type A had increased risk for infection with SARS-CoV-2 and blood type O had decreased risk of infection. Another early meta-analysis by Zaidi et al. cited that blood type A had increased odds of infection, type O had decreased odds of infection, type AB had increased risk of disease severity, and type B had decreased risk of demise.

As more multi-national data became available, as a result of global concerted efforts, larger studies produced data to further investigate this connection. Overall, the majority of studies reproduced similar data: type O had decreased risk of infection with SARS-CoV-2, while type A had increased risk of infection. One study in the United Kingdom failed to produce a relationship between blood types and COVID-19. As more data became available, several studies were able to study the association of blood group type with mortality and disease severity; however, the data regarding this is inconsistent. Gutierrez-Valencia et al. did not find an association with blood types and ICU admission or mechanical ventilation; however, they did note an increased risk of mortality in blood type A. Liu et al. and Pereira et al. demonstrated that there is also increased risk of mortality in blood type A. Jerico et al. noted a lower risk for ICU admission in blood type O. Goel et al. noted an increased risk of disease severity in blood type A. As evident, it seems that blood type A has increased risk of mortality and, likely, disease severity.

In this study, we aim to evaluate association of blood types with mortality and disease severity at a county hospital in Southern California. We will review charts for patients infected with SARS-CoV-2 during a two-year time period, evaluating mortality, oxygen requirements, and patient historical factors. Through this study, we aim to gain a better understanding of how blood group types may affect patient outcomes in the setting of COVID-19.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Blood Group Antigen Abnormality Blood Group Incompatibilities Diabetes Mellitus COVID-19 Pandemic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ABO + Group

All patient with blood type that does not include Rhesus Factor and COVID-19 Diagnosis

No Intervention

Intervention Type OTHER

Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups

ABO - Group

All patient with blood type that does not include Rhesus Factor and COVID-19 Diagnosis

No Intervention

Intervention Type OTHER

Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No Intervention

Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 18 years of age
* COVID-19 confirmed by laboratory testing (ICD10 U07.1)
* Pneumonia due to COVID-19 (ICD10 J12.82)
* Multisystem inflammatory syndrome from COVID in adults (ICD10 M35.81)
* Adult respiratory distress syndrome (ICD10 J80)
* Abnormal pulmonary function test (ICD10 R94.2)
* Intensive care unit admission for COVID-19